Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer’s Disease: Prophylactic and Therapeutic Applications

Molecular Neurobiology

Volumn 51, Issue 1, 2015, Pages 43-56

  Kou, Jinghong ^a   Yang, Junling ^a   Lim, Jeong Eun ^a   Pattanayak, Abhinandan ^a   Song, Min ^a   Planque, Stephanie ^b   Paul, Sudhir ^b   Fukuchi, Ken ichiro ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Adeno associated virus; Alzheimer s disease; Amyloid; Antibody; Immunotherapy; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN; ANTIBODY;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL; BIOCATALYSIS; C57BL MOUSE; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL HEMORRHAGE; CEREBROSPINAL FLUID; COMPLICATION; DEPENDOPARVOVIRUS; DISEASE MODEL; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; HEK293 CELL LINE; HIPPOCAMPUS; HUMAN; IMMUNOGLOBULIN GENE; INFLAMMATION; INJECTION; METABOLISM; MICROGLIA; MONOCYTE; NEOCORTEX; PATHOLOGY; SOLUBILITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; BIOCATALYSIS; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL HEMORRHAGE; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENES, IMMUNOGLOBULIN; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HIPPOCAMPUS; HUMANS; INFLAMMATION; INJECTIONS; MICE, INBRED C57BL; MICROGLIA; MONOCYTES; NEOCORTEX; PLAQUE, AMYLOID; SOLUBILITY;

EID: 84927927157     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8691-z     Document Type: Article

References (63)

1. Hardy J (2006) Amyloid double trouble. Nat Genet 38:11–12
2. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177
3. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J et al (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408:979–982
4. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D et al (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408:982–985
5. Check E (2002) Nerve inflammation halts trial for Alzheimer’s drug. Nature 415:462
6. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46–54
7. Sigurdsson EM, Wisniewski T, Frangione B (2002) A safer vaccine for Alzheimer’s disease? Neurobiol Aging 23:1001–1008
8. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM (2002) Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8:1270–1275
9. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64:94–101
10. Salloway S, Gregg K, Black R, Grundman M, Sperling R. (2009) Cognitive and functional outcomes from a phase II trial of bapineuzumab in mild to moderate Alzheimer’s disease. American Academy of Neurology Abs S32.002
11. Sperling R, Salloway S, Fox N, Barackos J, Morris K, Francis G, Black R, Grundman M (2009) Risk factors and clinical course associated with vasogenic edema in a phase II trial of bapineuzumab. Presentation at: 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden. http://www.stevenderoover.be/EFNS/Presentations/EFNS2012/WC220/. Accessed 08 Sept 2012
12. Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, Nitrini R, Sakaguchi H, Brioschi M, Billo G et al (2013) Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for Amyloid-Modifying Therapies. Ann Neurol 73(4):449–458
13. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX et al (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69:198–207
14. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1:24
15. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP et al (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25:629–636
16. Callaway E (2012) Alzheimer’s drugs take a new tack. Nature 489:13–14
17. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 37:943–948
18. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, Schade RF (2004) Autoimmunity in Alzheimer’s disease: Increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 25:1023–1032
19. Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M (2009) Autoantibodies against beta-amyloid are common in Alzheimer’s disease and help control plaque burden. Ann Neurol 65:24–31
20. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH et al (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc Natl Acad Sci U S A 106:12145–12150
21. Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Paul S (2008) Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev 7:391–397
22. Taguchi H, Planque S, Sapparapu G, Boivin S, Hara M, Nishiyama Y, Paul S (2008) Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem 283:36724–36733
23. Gao QS, Sun M, Rees AR, Paul S (1995) Site-directed mutagenesis of proteolytic antibody light chain. J Mol Biol 253:658–664
24. Ramsland PA, Terzyan SS, Cloud G, Bourne CR, Farrugia W, Tribbick G, Geysen HM, Moomaw CR, Slaughter CA, Edmundson AB (2006) Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody. Biochem J 395:473–481
25. Liu Y, Studzinski C, Beckett T, Guan H, Hersh MA, Murphy MP, Klein R, Hersh LB (2009) Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther 17:1381–1386
26. Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC (2004) Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci 24:991–998
27. Mukherjee A, Song E, Kihiko-Ehmann M, Goodman JP Jr, Pyrek JS, Estus S, Hersh LB (2000) Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci 20:8745–8749
28. Chesneau V, Vekrellis K, Rosner MR, Selkoe DJ (2000) Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization. Biochem J 351(Pt 2):509–516
29. Kou J, Kim HD, Pattanyak A, Song M, Lim J, Taguchi H, Paul S, Cirrito JR, Ponnazhagan S, Fukuchi K (2011) Anti-Abeta single-chain antibody brain delivery via AAV reduces amyloid load but may increase cerebral hemorrhages in an Alzheimer mouse model. J Alzheimers Dis 27:23–28
30. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193–199
31. Grimm D, Kay MA, Kleinschmidt JA (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 7:839–850
32. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ Jr, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW et al (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28:158–167
33. Fukuchi KI, Tahara K, Kim HD, Maxwell JA, Lewis TL, Accavitti-Loper M, Kim H, Ponnazhagan S, Lalonde R (2006) Anti-Aß single chain antibody delivery via adeno-associated virus for treatment of Alzheimer’s disease. Neurobiol Dis 23:502–511
34. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL et al (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159–170
35. DeMattos RB, Bales KR, Parsadanian M, O’Dell MA, Foss EM, Paul SM, Holtzman DM (2002) Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer’s disease. J Neurochem 81:229–236
36. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A et al (2009) Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29:3453–3462
37. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69:1002–1010
38. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA et al (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363–372
39. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol 14:11–20
40. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379
41. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D (2004) Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 15:11–20
42. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D et al (2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65:1040–1048
43. Moreth J, Mavoungou C, Schindowski K (2013) Passive anti-amyloid immunotherapy in Alzheimer’s disease: What are the most promising targets? Immun Ageing 10:18
44. Tayeb HO, Murray ED, Price BH, Tarazi FI (2013) Bapineuzumab and solanezumab for Alzheimer’s disease: Is the ‘amyloid cascade hypothesis’ still alive? Expert Opin Biol Ther 13:1075–1084
45. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK et al (2012) An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32:9677–9689
46. Fukuchi KI, Accavitti-Loper M, Kim HD, Tahara K, Cao Y, Lewis TL, Caughey RC, Kim H, Lalonde R (2006) Amelioration of amyloid load by anti-A[beta] single-chain antibody in Alzheimer mouse model. Biochem Biophys Res Commun 344:79–86
47. Kou J, Song M, Pattanayak A, Lim J, Yang J, Cao D, Li L, Fukuchi K (2012) Combined treatment of Aß immunization with statin in a mouse model of Alzheimer’s disease. J Neuroimmunol 244:70–83
48. Cearley CN, Wolfe JH (2006) Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13:528–537
49. Cearley CN, Wolfe JH (2007) A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 27:9928–9940
50. Van der Perren A, Toelen J, Carlon M, Van Den Haute C, Coun F, Heeman B, Reumers V, Vandenberghe LH, Wilson JM, Debyser Z et al (2011) Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Ther 18:517–527
51. Samaranch L, Salegio EA, San SW, Kells AP, Bringas JR, Forsayeth J, Bankiewicz KS (2013) Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 24:526–532
52. Harry GJ (2013) Microglia during development and aging. Pharmacol Ther 139:313–326
53. Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J (2008) Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer’s disease: Age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 28:11650–11661
54. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K et al (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916–919
55. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE (2002) Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer’s disease. Peptides 23:2223–2226
56. Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, Higuchi M, Staufenbiel M, Muramatsu S, Saido TC (2013) Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep 3:1472
57. Carty N, Nash KR, Brownlow M, Cruite D, Wilcock D, Selenica ML, Lee DC, Gordon MN, Morgan D (2013) Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP + PS1 transgenic mice. PLoS ONE 8:e59626
58. Tucker HM, Kihiko-Ehmann M, Estus S (2002) Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen. J Neurosci Res 70:249–255
59. Fu H, Muenzer J, Samulski RJ, Breese G, Sifford J, Zeng X, McCarty DM (2003) Self-complementary adeno-associated virus serotype 2 vector: Global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther 8:911–917
60. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59–65
61. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, Fyfe J, Moullier P, Colle MA, Barkats M (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17:1187–1196
62. Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM (2011) Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 19:1025–1033
63. Spampanato C, De LE, Dama P, Gargiulo A, Fraldi A, Sorrentino NC, Russo F, Nusco E, Auricchio A, Surace EM et al (2011) Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Mol Ther 19:860–869